HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mozley, P. D. Articles by Alavi, A. Search for Related Content PubMed PubMed Citation Articles by Mozley, P. D. Articles by Alavi, A.

The Dosimetry of Iodine-123-Labeled TISCH: A SPECT Imaging Agent for the D1 Dopamine Receptor

Division of Nuclear Medicine, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania

Correspondence: For correspondence or reprints contact: P. David Mozley, MD, Division of Nuclear Medicine, 110 Donner Building, H.U.P., 3400 Spruce St., Philadelphia, PA 19104.

ABSTRACT

TISCH is an iodinated D1 specific dopamine receptor antagonist that may be useful as a SPECT imaging agent. This report documents its pharmacological safety in animals and its radiation dosimetry in humans. The dose of radiation that ¹²³I-TISCH delivered to seven healthy subjects was estimated with the absorbed fraction technique. Conjugate images of the body were serially acquired for up to 24 hr after the administration of a known amount of activity. The count rates in the organs that could be visualized were measured on each image. These count rates were corrected for attenuation with ¹²³I transmission scans. The doses to the other organs that did not take up enough activity to be visualized on the images were estimated with established models. The dosimetry was calculated for each subject individually before the results were averaged. Rapid biological washout minimizes the radiation exposure to most organs. The dose to the large bowel is limiting in healthy volunteers. The proximal colon receives about 0.67 red/mCi (180 µGy/MBq) or about 5 rads for every 7.5 mCi of TISCH injected. This low radiation burden should make it feasible to study the D1 dopamine receptor in patients who have neuropsychiatric disorders before and after treatment.

This article has been cited by other articles:

				A. B. Newberg, N. A. Wintering, K. Plossl, J. Hochold, M. G. Stabin, M. Watson, D. Skovronsky, C. M. Clark, M.-P. Kung, and H. F. Kung Safety, Biodistribution, and Dosimetry of 123I-IMPY: A Novel Amyloid Plaque-Imaging Agent for the Diagnosis of Alzheimer's Disease J. Nucl. Med., May 1, 2006; 47(5): 748 - 754. [Abstract] [Full Text] [PDF]

				A. B. Newberg, K. Plossl, P. D. Mozley, J. B. Stubbs, N. Wintering, M. Udeshi, A. Alavi, T. Kauppinen, and H. F. Kung Biodistribution and Imaging with 123I-ADAM: A Serotonin Transporter Imaging Agent J. Nucl. Med., May 1, 2004; 45(5): 834 - 841. [Abstract] [Full Text] [PDF]